 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Targeted Mass Spec Slowly but Steadily Moving Toward Broader Commercial, Clinical Adoption
September 21, 2012
Targeted Mass Spec Slowly but Steadily Moving Toward Broader Commercial, Clinical Adoption
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Big Names Join Clinical Proteomics Push in 2011, Offering Ray of Optimism Amidst Difficult Year
January 6, 2012 / ProteoMonitor - Leigh Anderson Launches New Firm to Commercialize SISCAPA Technology
June 17, 2011 / ProteoMonitor - 2012 Sees Rise of Targeted Proteomics and DIA-MS, Continued Clinical Push by Big Industry Players
January 4, 2013 / ProteoMonitor - Researchers Develop Seven-Second MRM-MS Workflow Using Agilent's RapidFire Technology
November 16, 2012 / ProteoMonitor - BRIMS-Led Study Suggests Clinical Viability of SRM-MS, Vendors' Role in Clinical Proteomics Process
June 8, 2012 / ProteoMonitor